Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer DMD Gene Therapy Phase III Trial Faces A US Delay; Can Sarepta Close The Gap?

Sarepta Hopes To Meet With FDA Midyear

Executive Summary

Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.

You may also be interested in...



Pfizer Gets AAV Capsid Rights From Voyager For Gene Therapy R&D

Deal Snapshot: Pfizer has 12 months to evaluate a pair of AAV capsids from Voyager’s TRACER platform for use as delivery mechanisms in gene therapy candidates for neurologic and CV indications.

Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected

Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.

JAK-Inhibitor Review Delays Spur Talk Of US FDA Panel Meeting On Class Safety

After Pfizer saw increased risks in a surveillance study of Xeljanz, three other products have also seen their user fee dates pushed back; if FDA were to convene an expert panel, it could lead to more consistent labeling across the class, as requested in a recent citizen petition.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel